PMID- 22197492
OWN - NLM
STAT- MEDLINE
DCOM- 20120824
LR  - 20191210
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 33
IP  - 1
DP  - 2012 Jan
TI  - Modulation of neuropeptide FF (NPFF) receptors influences the expression of 
      amphetamine-induced conditioned place preference and amphetamine withdrawal 
      anxiety-like behavior in rats.
PG  - 156-63
LID - 10.1016/j.peptides.2011.12.002 [doi]
AB  - Many data indicate that endogenous opioid system is involved in 
      amphetamine-induced behavior. Neuropeptide FF (NPFF) possesses opioid-modulating 
      properties. The aim of the present study was to determine whether pharmacological 
      modulation of NPFF receptors modify the expression of amphetamine-induced 
      conditioned place preference (CPP) and amphetamine withdrawal anxiety-like 
      behavior, both processes relevant to drug addiction/abuse. 
      Intracerebroventricular (i.c.v.) injection of NPFF (5, 10, and 20 nmol) inhibited 
      the expression of amphetamine CPP at the doses of 10 and 20 nmol. RF9, the NPFF 
      receptors antagonist, reversed inhibitory effect of NPFF (20 nmol, i.c.v.) at the 
      doses of 10 and 20 nmol and did not show any effect in amphetamine- and saline 
      conditioned rats. Anxiety-like effect of amphetamine withdrawal was measured 24h 
      after the last (14 days) amphetamine (2.5mg/kg, i.p.) treatment in the elevated 
      plus-maze test. Amphetamine withdrawal decreased the percent of time spent by 
      rats in the open arms and the percent of open arms entries. RF9 (5, 10, and 20 
      nmol, i.c.v.) significantly reversed these anxiety-like effects of amphetamine 
      withdrawal and elevated the percent of time spent by rats in open arms at doses 
      of 5 and 10 nmol, and the percent of open arms entries in all doses used. NPFF 
      (20 nmol) pretreatment inhibited the effect of RF9 (10 nmol). Our results 
      indicated that stimulation or inhibition of NPFF receptors decrease the 
      expression of amphetamine CPP and amphetamine withdrawal anxiety, respectively. 
      These findings may have implications for a better understanding of the processes 
      involved in amphetamine dependence.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - Kotlinska, J H
AU  - Kotlinska JH
AD  - Department of Pharmacology and Pharmacodynamics, Medical University, Lublin, 
      Poland. jolka.kotlinska@umlub.pl
FAU - Gibula-Bruzda, E
AU  - Gibula-Bruzda E
FAU - Koltunowska, D
AU  - Koltunowska D
FAU - Raoof, H
AU  - Raoof H
FAU - Suder, P
AU  - Suder P
FAU - Silberring, J
AU  - Silberring J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111216
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Dipeptides)
RN  - 0 (Oligopeptides)
RN  - 0 (Receptors, Neuropeptide)
RN  - 0 (adamantylcarbonyl-arginyl-phenylalaninamide)
RN  - 0 (neuropeptide FF receptor)
RN  - 99566-27-5 
      (phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide)
RN  - CK833KGX7E (Amphetamine)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/analogs & derivatives/pharmacology
MH  - Amphetamine/*adverse effects
MH  - Animals
MH  - Anxiety/*chemically induced
MH  - Behavior, Animal
MH  - Conditioning, Psychological
MH  - Dipeptides/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Male
MH  - Maze Learning/drug effects
MH  - Oligopeptides/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Neuropeptide/antagonists & inhibitors/*metabolism
MH  - *Substance Withdrawal Syndrome/drug therapy
EDAT- 2011/12/27 06:00
MHDA- 2012/08/25 06:00
CRDT- 2011/12/27 06:00
PHST- 2011/07/27 00:00 [received]
PHST- 2011/12/06 00:00 [revised]
PHST- 2011/12/06 00:00 [accepted]
PHST- 2011/12/27 06:00 [entrez]
PHST- 2011/12/27 06:00 [pubmed]
PHST- 2012/08/25 06:00 [medline]
AID - S0196-9781(11)00513-4 [pii]
AID - 10.1016/j.peptides.2011.12.002 [doi]
PST - ppublish
SO  - Peptides. 2012 Jan;33(1):156-63. doi: 10.1016/j.peptides.2011.12.002. Epub 2011 
      Dec 16.